Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Kinnate Biopharma (KNTE)
NASDAQ:KNTE
Kinnate Biopharma (KNTE) Stock Price & Analysis
162 Followers
KNTE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.32 - $15.86
Previous Close$3.73
Volume216.78K
Average Volume (3M)404.58K
Market Cap
$173.72M
Enterprise Value-$23.32M
Total Cash (Recent Filing)$200.98M
Total Debt (Recent Filing)$3.95M
Price to Earnings (P/E)-1.4
Beta1.39
Next Earnings
Aug 14, 2023EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding46,572,594
10 Day Avg. Volume372,441
30 Day Avg. Volume404,579
Standard Deviation0.26
R-Squared0.00184
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)8.10
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.18
Forecast
1Y Price Target
$17.08Price Target Upside357.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Kinnate Biopharma News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KNTE FAQ
What was Kinnate Biopharma’s price range in the past 12 months?
Kinnate Biopharma lowest stock price was $2.32 and its highest was $15.86 in the past 12 months.
What is Kinnate Biopharma’s market cap?
Currently, no data Available
When is Kinnate Biopharma’s upcoming earnings report date?
Kinnate Biopharma’s upcoming earnings report date is Aug 14, 2023 which is in 78 days.
How were Kinnate Biopharma’s earnings last quarter?
Kinnate Biopharma released its earnings results on May 11, 2023. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.711 by -$0.019.
Is Kinnate Biopharma overvalued?
According to Wall Street analysts Kinnate Biopharma’s price is currently Undervalued.
Does Kinnate Biopharma pay dividends?
Kinnate Biopharma does not currently pay dividends.
What is Kinnate Biopharma’s EPS estimate?
Kinnate Biopharma’s EPS estimate is -$0.75.
How many shares outstanding does Kinnate Biopharma have?
Kinnate Biopharma has 46,572,594 shares outstanding.
What happened to Kinnate Biopharma’s price movement after its last earnings report?
Kinnate Biopharma reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.711. Following the earnings report the stock price went up 5.307%.
Which hedge fund is a major shareholder of Kinnate Biopharma?
Among the largest hedge funds holding Kinnate Biopharma’s share is RA Capital Management. It holds Kinnate Biopharma’s shares valued at 27M.
---
Kinnate Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.08 (357.91% Upside)
$17.08 (357.91% Upside)
Blogger Sentiment
Neutral
KNTE Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 902.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 33.4%
Last 30 Days ▲ 33.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.45%
12-Months-Change
Fundamentals
Return on Equity
-47.17%
Trailing 12-Months
Asset Growth
-30.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kinnate Biopharma
Kinnate Biopharma Inc a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's product candidate is KIN002787, which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor it is developing for the treatment of patients with lung cancer, melanoma and other solid tumors. Its KIN003 program is evaluating Fibroblast Growth Factor Receptors (FGFR) inhibitor candidates for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining.
---
Top 5 ETFs holding KNTE
iShares NASDAQ US Biotechnology UCITS ETF
$83.12K
Invesco Nasdaq Biotechnology ETF
$3.46K
Up to five ETFs with an Outperform Smart Score that hold KNTE. The ETFs are listed according to market value of KNTE within the ETF
---
---